KR100345825B1 - Method for Extraction, Isolation and Identification of Serotonins, Lignans and Flavonoids Improved Bone Formation from Safflower(Carthamus tinctorious L.) Seeds - Google Patents
Method for Extraction, Isolation and Identification of Serotonins, Lignans and Flavonoids Improved Bone Formation from Safflower(Carthamus tinctorious L.) Seeds Download PDFInfo
- Publication number
- KR100345825B1 KR100345825B1 KR1020000003048A KR20000003048A KR100345825B1 KR 100345825 B1 KR100345825 B1 KR 100345825B1 KR 1020000003048 A KR1020000003048 A KR 1020000003048A KR 20000003048 A KR20000003048 A KR 20000003048A KR 100345825 B1 KR100345825 B1 KR 100345825B1
- Authority
- KR
- South Korea
- Prior art keywords
- serotonin
- safflower
- methanol
- seeds
- acacetin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 244000020518 Carthamus tinctorius Species 0.000 title claims abstract description 58
- 235000003255 Carthamus tinctorius Nutrition 0.000 title claims abstract description 58
- 230000011164 ossification Effects 0.000 title claims abstract description 15
- 229930013686 lignan Natural products 0.000 title abstract description 24
- 235000009408 lignans Nutrition 0.000 title abstract description 24
- 150000005692 lignans Chemical class 0.000 title abstract description 24
- 229930003935 flavonoid Natural products 0.000 title abstract description 17
- 235000017173 flavonoids Nutrition 0.000 title abstract description 17
- 150000002215 flavonoids Chemical class 0.000 title abstract description 16
- 238000000605 extraction Methods 0.000 title description 13
- WLYGSPLCNKYESI-RSUQVHIMSA-N Carthamin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[C@@]1(O)C(O)=C(C(=O)\C=C\C=2C=CC(O)=CC=2)C(=O)C(\C=C\2C([C@](O)([C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(O)=C(C(=O)\C=C\C=3C=CC(O)=CC=3)C/2=O)=O)=C1O WLYGSPLCNKYESI-RSUQVHIMSA-N 0.000 title description 2
- 241000208809 Carthamus Species 0.000 title description 2
- 238000002955 isolation Methods 0.000 title 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 90
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims abstract description 90
- 229940076279 serotonin Drugs 0.000 claims abstract description 44
- 238000000034 method Methods 0.000 claims abstract description 15
- 238000004440 column chromatography Methods 0.000 claims abstract description 11
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 claims abstract description 10
- DANYIYRPLHHOCZ-UHFFFAOYSA-N 5,7-dihydroxy-4'-methoxyflavone Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 DANYIYRPLHHOCZ-UHFFFAOYSA-N 0.000 claims description 32
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 24
- 235000009962 acacetin Nutrition 0.000 claims description 15
- 235000013824 polyphenols Nutrition 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 12
- -1 polyphenol compound Chemical class 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- NLZCOTZRUWYPTP-MIUGBVLSSA-N 5-hydroxy-2-(4-methoxyphenyl)-7-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one Chemical compound C1=CC(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 NLZCOTZRUWYPTP-MIUGBVLSSA-N 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 230000001737 promoting effect Effects 0.000 claims description 8
- 239000004952 Polyamide Substances 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 229920002647 polyamide Polymers 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 2
- NLZCOTZRUWYPTP-UHFFFAOYSA-N acacetin-7-O-beta-D-galactoside Natural products C1=CC(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2OC1C(O)C(O)C(O)C(CO)O1 NLZCOTZRUWYPTP-UHFFFAOYSA-N 0.000 claims 4
- GWOKWCRSUJQOMD-UHFFFAOYSA-N tilianin Natural products C1=CC(OC)=CC=C1C(OC1=C2)=CC(=O)C1=CC=C2OC1C(O)C(O)C(O)C(CO)O1 GWOKWCRSUJQOMD-UHFFFAOYSA-N 0.000 claims 4
- 239000012141 concentrate Substances 0.000 claims 3
- 238000005238 degreasing Methods 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 238000010298 pulverizing process Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 16
- 208000001132 Osteoporosis Diseases 0.000 abstract description 11
- 239000000401 methanolic extract Substances 0.000 abstract description 11
- 102000039446 nucleic acids Human genes 0.000 abstract description 9
- 108020004707 nucleic acids Proteins 0.000 abstract description 9
- 150000007523 nucleic acids Chemical class 0.000 abstract description 9
- 239000004615 ingredient Substances 0.000 abstract description 4
- 238000000926 separation method Methods 0.000 abstract description 4
- 238000004128 high performance liquid chromatography Methods 0.000 abstract description 3
- 239000007788 liquid Substances 0.000 abstract description 3
- 150000001408 amides Chemical class 0.000 abstract 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 19
- 230000008018 melting Effects 0.000 description 18
- 238000002844 melting Methods 0.000 description 18
- 229960005309 estradiol Drugs 0.000 description 9
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 9
- 235000006539 genistein Nutrition 0.000 description 9
- 229940045109 genistein Drugs 0.000 description 9
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 206010017076 Fracture Diseases 0.000 description 8
- WLZPAFGVOWCVMG-FPYGCLRLSA-N N6-cis-p-Coumaroylserotonin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)NCCC1=CNC2=CC=C(O)C=C12 WLZPAFGVOWCVMG-FPYGCLRLSA-N 0.000 description 8
- 239000003075 phytoestrogen Substances 0.000 description 8
- 244000068988 Glycine max Species 0.000 description 7
- 235000010469 Glycine max Nutrition 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 150000002989 phenols Chemical class 0.000 description 7
- 208000010392 Bone Fractures Diseases 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 230000003078 antioxidant effect Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000000262 estrogen Substances 0.000 description 6
- 229940011871 estrogen Drugs 0.000 description 6
- 150000008442 polyphenolic compounds Chemical class 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 150000003431 steroids Chemical class 0.000 description 5
- MATGKVZWFZHCLI-LSDHHAIUSA-N (-)-matairesinol Chemical compound C1=C(O)C(OC)=CC(C[C@@H]2[C@H](C(=O)OC2)CC=2C=C(OC)C(O)=CC=2)=C1 MATGKVZWFZHCLI-LSDHHAIUSA-N 0.000 description 4
- WGHKJYWENWLOMY-XVNBXDOJSA-N N-feruloylserotonin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)NCCC=2C3=CC(O)=CC=C3NC=2)=C1 WGHKJYWENWLOMY-XVNBXDOJSA-N 0.000 description 4
- 235000019485 Safflower oil Nutrition 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- WGHKJYWENWLOMY-CLTKARDFSA-N cis-Moschamine Natural products C1=C(O)C(OC)=CC(\C=C/C(=O)NCCC=2C3=CC(O)=CC=C3NC=2)=C1 WGHKJYWENWLOMY-CLTKARDFSA-N 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 235000000055 matairesinol Nutrition 0.000 description 4
- RNXYRAQIZQGUIK-UHFFFAOYSA-N matairesinol Natural products COc1cc(CC2OCC(=O)C2Cc3ccc(O)c(OC)c3)ccc1O RNXYRAQIZQGUIK-UHFFFAOYSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000003813 safflower oil Substances 0.000 description 4
- 235000005713 safflower oil Nutrition 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- 208000020084 Bone disease Diseases 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 210000002449 bone cell Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229930182833 estradiol Natural products 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 150000002515 isoflavone derivatives Chemical class 0.000 description 3
- 239000002032 methanolic fraction Substances 0.000 description 3
- 238000002953 preparative HPLC Methods 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- MJYQFWSXKFLTAY-OVEQLNGDSA-N (2r,3r)-2,3-bis[(4-hydroxy-3-methoxyphenyl)methyl]butane-1,4-diol;(2r,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O.C1=C(O)C(OC)=CC(C[C@@H](CO)[C@H](CO)CC=2C=C(OC)C(O)=CC=2)=C1 MJYQFWSXKFLTAY-OVEQLNGDSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 238000000134 MTT assay Methods 0.000 description 2
- 231100000002 MTT assay Toxicity 0.000 description 2
- 206010030247 Oestrogen deficiency Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- 230000001833 anti-estrogenic effect Effects 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 2
- 239000000328 estrogen antagonist Substances 0.000 description 2
- 230000001076 estrogenic effect Effects 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 235000004426 flaxseed Nutrition 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 229930013032 isoflavonoid Natural products 0.000 description 2
- 150000003817 isoflavonoid derivatives Chemical class 0.000 description 2
- 235000012891 isoflavonoids Nutrition 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 235000017807 phytochemicals Nutrition 0.000 description 2
- 229930000223 plant secondary metabolite Natural products 0.000 description 2
- 235000021067 refined food Nutrition 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- PUETUDUXMCLALY-HOTGVXAUSA-N (-)-secoisolariciresinol Chemical compound C1=C(O)C(OC)=CC(C[C@@H](CO)[C@H](CO)CC=2C=C(OC)C(O)=CC=2)=C1 PUETUDUXMCLALY-HOTGVXAUSA-N 0.000 description 1
- XKZQKPRCPNGNFR-UHFFFAOYSA-N 2-(3-hydroxyphenyl)phenol Chemical compound OC1=CC=CC(C=2C(=CC=CC=2)O)=C1 XKZQKPRCPNGNFR-UHFFFAOYSA-N 0.000 description 1
- 229930183010 Amphotericin Natural products 0.000 description 1
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- 240000006240 Linum usitatissimum Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229940009444 amphotericin Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 201000011529 cardiovascular cancer Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000004821 effect on bone Effects 0.000 description 1
- 238000002451 electron ionisation mass spectrometry Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- OGFXBIXJCWAUCH-UHFFFAOYSA-N meso-secoisolariciresinol Natural products C1=2C=C(O)C(OC)=CC=2CC(CO)C(CO)C1C1=CC=C(O)C(OC)=C1 OGFXBIXJCWAUCH-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N palmityl palmitate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000001054 red pigment Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 235000004239 secoisolariciresinol Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 244000045561 useful plants Species 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000001052 yellow pigment Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
- A47J—KITCHEN EQUIPMENT; COFFEE MILLS; SPICE MILLS; APPARATUS FOR MAKING BEVERAGES
- A47J37/00—Baking; Roasting; Grilling; Frying
- A47J37/06—Roasters; Grills; Sandwich grills
- A47J37/0623—Small-size cooking ovens, i.e. defining an at least partially closed cooking cavity
- A47J37/0629—Small-size cooking ovens, i.e. defining an at least partially closed cooking cavity with electric heating elements
-
- A—HUMAN NECESSITIES
- A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
- A47J—KITCHEN EQUIPMENT; COFFEE MILLS; SPICE MILLS; APPARATUS FOR MAKING BEVERAGES
- A47J36/00—Parts, details or accessories of cooking-vessels
- A47J36/02—Selection of specific materials, e.g. heavy bottoms with copper inlay or with insulating inlay
- A47J36/04—Selection of specific materials, e.g. heavy bottoms with copper inlay or with insulating inlay the materials being non-metallic
Landscapes
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
본 발명은 홍화씨로부터 뼈 형성을 촉진하는 세로토닌, 리그난 및 플라보노이드 성분의 추출방법에 관한 것으로, 볶은 홍화씨를 핵산으로 탈지하여 얻은 잔사를 메탄올로 열탕 추출하고 여과·농축한 후 다이아이온 HP-20 및 폴리아마이드 C-200으로 칼럼크로마토그래피를 실시하여 얻어진 60%, 80% 및 100% 메탄올 추출물을 세파덱스 LH-20으로 칼럼크로마토그래피 및 분취-고속액체크로마토그래피를 실시하여 순수 분리한 세로토닌, 리그난 및 플라보노이드 성분은 골다공증 및 골절 치료에 뛰어난 효과가 있다.The present invention relates to a method for extracting serotonin, lignan and flavonoid components that promote bone formation from safflower seeds. The roasted safflower seeds are degreased with nucleic acid, and the residue is extracted with hot methanol by methanol, filtered and concentrated. Column chromatography with amide C-200 and column chromatography with Sephadex LH-20 - high performance liquid chromatography on 60%, 80% and 100% methanol extracts obtained by pure-liquid separation of serotonin, lignan and flavonoids Ingredients have excellent effects on the treatment of osteoporosis and fracture.
Description
본 발명은 홍화씨로부터 뼈 형성을 촉진하는 세로토닌, 리그난 및 플라보노이드 성분의 추출방법에 관한 것이다. 더욱 상세하게는, 볶은 홍화씨로부터 뼈 형성을 촉진하여 골절 및 골다공증의 예방 및 치료제로 유용한 페루로일세로토닌 및 쿠마릴세로토닌과 같은 세로토닌 성분, 마타이레시놀 및 하이드록시악티게닌과 같은 리그난 성분 및 틸리아닌 및 아카세틴과 같은 플라보노이드 성분의 추출방법에 관한 것이다The present invention relates to a method for extracting serotonin, lignan and flavonoid components which promote bone formation from safflower seeds. More particularly, the present invention relates to a method for inhibiting osteoporosis by stimulating bone formation from roasted safflower seed to provide a serotonin component such as perroyl serotonin and coumaryl serotonin useful as a preventive and therapeutic agent for fracture and osteoporosis, a lignan component such as matairecinol and hydroxyactigencine, And a method of extracting flavonoid components such as acacetin
홍화(紅花, 영명: Safflower, 생약명:Carthamus tinctoriousL.)은 국화과(Compositae)에 속하는 일년생 초목으로서 원산지는 아프카니스탄의 산악지대 또는 에티오피아이다(이창복, 대한식물도감, 1980). 홍화꽃은 수용성의 황색색소와 불용성의 적색색소를 함유하고 예로부터 염료로 널리 사용되어 왔으며(육창수, 한국본초학, 1981), 아울러 한방에서 어혈, 통경 및 고지혈증 치료제로서 홍화탕, 활혈통경탕 등의 처방제로 널리 이용되어 왔다(본초학, 이상인, 1980).Safflower (Carthamus tinctorious L.) is a perennial plant belonging to the Compositae , and its origin is the mountainous region of Ethiopia or Ethiopia (Lee Chang-bok, Korean Botanical Garden, 1980). Safflower has been widely used as a dye (Yong Chang Soo, Korean Herbal Medicine, 1981), containing water-soluble yellow pigment and insoluble red pigment, and also has been used as a medicament for treatment of eosinophilic, hyperlipidemic and hyperlipidemia, Have been widely used as prescription drugs (Herbology, Lee, 1980).
한편, 홍화씨는 한국, 중국 및 일본 등지에서 진정 및 보혈 등의 약용으로 사용되어 왔으며(생약학, 한대석, 1995), 특히 미국 및 인도에서는 식용유 생산용으로 재배되고 있는 유용한 자원식물이다(안덕균, 육창수, 현대본초학, 1975). 홍화씨 기름에는 비타민 E인 토코페롤, 비타민 F인 리놀렌산 등과 칼슘, 알루미늄 및 브롬과 같은 천연 미네랄 성분이 풍부하게 함유되어 있어 건강식품의 소재로서 널리 이용되어 왔다(유태종, 건강식품, 1995). 특히 홍화씨는 다량의 불포화지방산을 함유하고 있어 영양상으로 중요할 뿐 아니라, 특히 리놀렌산의 함량이 높아 항혈전 및 항고혈압성 신소재로서 각광을 받고 있다(박인규, 김봉제, 동의보감, 1989; Khan, A. R., Thesis, 18: 81-87, 1929). 또한 홍화씨 분말의 투여가 골절치유 및 지질대사개선 효과가 있음이 최근 밝혀지면서 그를 이용한 기능성 식품의 개발이 활발히 이루어지고 있다(김준환 등, 한국식품영양과학지, 27(3): 698-704, 1998; 김준환 등, 한국식품영양과학지, 28(3): 625-631, 1999). 최근 홍화씨가 골다공증, 골절 등과 같은 뼈 질환에 놀랄 만큼 뛰어난 효과가 있음이 민간인들 사이에 알려지면서 그 생산량과 소비가 크게 증가하고 있다. 그러나 지금까지 홍화씨의 뼈질환치료 효과를 과학적으로 규명한 연구는 거의 없는 실정이다.On the other hand, safflower seeds have been used as calming and blood medicines in Korea, China and Japan (Haejakgwa, Han Dae Suk, 1995), and especially useful plants for the production of edible oils in the US and India (Ahn, Modern Hebrews, 1975). Safflower oil has been widely used as a health food material because it contains vitamin E tocopherol, vitamin F, linolenic acid, and natural minerals such as calcium, aluminum and bromine (Yoo Tae Jong, Health Food, 1995). In particular, safflower seeds contain a large amount of unsaturated fatty acids, and thus they are not only nutritionally important, but also have a high content of linolenic acid, thus being attracting attention as antithrombotic and antihypertensive new materials (Park, In, Kim, Thesis, 18: 81-87, 1929). In addition, as the administration of safflower seed powder has been reported to have an effect of improving fracture healing and lipid metabolism, functional foods using the safflower seeds have been actively developed (Kim, Jun-Hwan, et al., Korean Journal of Food Science and Nutrition, 27 (3): 698-704, 1998 ; Kim, Joon Hwan et al., The Korean Journal of Food and Nutrition, 28 (3): 625-631, 1999). Recently, the production and consumption of safflower seed has increased remarkably as it is known among the civilians that there is a remarkable effect on bone diseases such as osteoporosis and fracture. However, until now, there have been few studies that scientifically investigated the effect of safflower seeds on bone diseases.
한편, 홍화씨 기름을 짜고 부산물로 얻어지는 홍화 유박(oil cake)은 단백질 및 식이성 섬유소의 급원으로서 중요할 뿐 아니라 세로토닌, 리그난 및 플라보노이드와 같은 항산화성 폴리페놀화합물을 함유하고 있어 고혈압, 고지혈증 및 동맥경화증 치료제로서 주목을 받고 있다(Sakamura S.et al.,Agric. Biol. Chem., 44(12): 2951-2954, 1980; Zhang, H. L.et al.,Chem. Pharm. Bull., 44(4): 874-876, 1996; Zhang, H. L.et al.,Chem. Pharm. Bull. 45(2): 1910-1914, 1997). 그러나 홍화 유박은 쓴맛, 설사 및 독성을 나타내는 리그난 및 스테로이드를 함유하고 있어 지금까지 그것을 식품이나 사료로 사용하는 것이 부분적으로 제한되어 왔으며(Palter R. Lundin, R. E., Phytochem., 9: 2407-2409, 1970; Palter, R.et al., Phytochem.,11: 2871-2874, 1972; Palter, R.et al., Phytochem., 11: 2327-2328, 1972), 홍화의 가시로 인해 홍화를 그대로 식이용으로 사용하는 데 어려움이 있었다. 따라서 현재 홍화씨를 볶음 처리하여 위의 부작용을 완하시키는 동시에, 항산화 활성 및 우수한 향기의 생성을 유발시키기 위하여 현재 홍화씨를 일부 볶아 가공하고 있다(Roh J. S.et al., 8(2): 88-92, 1999; Choi S. W.,J.Food Sci. Nutr., 1999).On the other hand, safflower oil cake obtained as a by-product of safflower oil is important as a source of protein and dietary fiber, and also contains antioxidative polyphenol compounds such as serotonin, lignan and flavonoid, has attracted attention as a therapeutic agent (Sakamura S. et al, Agric Biol Chem, 44 (12):........ 2951-2954, 1980; Zhang, HL et al, Chem Pharm Bull, 44 (4) : 874-876, 1996; Zhang, HL et al ., Chem. Pharm. Bull . 45 (2): 1910-1914,1997). However, safflower oil contains lignans and steroids that exhibit bitter taste, diarrhea and toxicity, and so far it has been limited in part to use as food or feed (Palter R. Lundin, RE, Phytochem., 9: 2407-2409, 1970; Palter, R. et al, Phytochem, 11: 2871-2874, 1972; Palter, R. et al, Phytochem, 11:. 2327-2328 expression, 1972), safflower as due to the safflower visible... There was a difficulty in using by using. Therefore, safflower seeds are roasted to some extent to induce antioxidant activity and excellent aroma (Roh JS et al. , 8 (2): 88-92, 1999, Choi SW, J. Food Sci., Nutr. , 1999).
이와 같이, 지금까지 홍화꽃 및 종자로부터 생리활성물질의 분리 및 그들의 생리적·약리적 작용을 밝히려는 연구와 더불어 홍화를 이용한 천연색소 및 가공식품의 개발에 관한 연구는 수행되어 왔으나, 홍화씨의 뼈 질환 치료 효과 및 활성성분의 분리에 관한 연구는 거의 없는 실정이다. 따라서 홍화씨의 뼈 질환 치료 효과를 과학적으로 입증할 필요성이 절실하다.Thus, studies on the separation of physiologically active substances from safflower flowers and seeds and their physiological and pharmacological actions have been carried out, and studies on the development of natural pigments and processed foods using safflower have been carried out. However, There have been few studies on the effect and the separation of active ingredients. Therefore, it is urgent to scientifically prove the effect of safflower seeds on bone diseases.
최근의 역학적 보고와 임상학적 연구 보고에 의하면 여러 곡류 및 과채류에 함유되어 있는 항산화성 식물화학물질(phytochemicals)은 비타민을 능가할 차세대 요법의 약으로서 암 뿐만 아니라 협심증, 고혈압, 당뇨병 및 치매와 같은 여러 퇴행성 만성질환을 예방·치료하는 데 탁월한 효과가 있는 것으로 밝혀지고 있다(Hasler, C. M., Food Technology, 52(11): 63-70, 1998). 특히 이러한 식물화학물질중 최근 가장 주목을 받고 있는 것이 바로 이소플라보노이드(isoflavonoids) 및 리그난(lignans) 성분이다(Adlercreutz H., BailliersClin. Endocrinol. Metab.12(4): 605-623, 1998). 이들 성분은 디페놀(diphenol)계 화합물로서 그 구조와 분자량이 스테로이드 에스트로겐(steroid estrogen)과 유사하여 소위 피토에스트로겐(phytoestrogen)으로 불리우고 있다. 피토에스트로겐은 안티에스트로겐 (antiestrogen) 및 에스트로겐(estrogen) 활성을 지니고 있어 호르몬 의존성의 유방암, 전립선암 및 대장암을 예방해줄 뿐 아니라 폐경기 이후 여성에게 많이 발생하는 심장병, 고혈압 및 골다공증을 예방하는 것으로 밝혀지고 있다(Dwyer, J. T.et al., J. Am. Diet. Assoc.,94: 739-743, 1994; Tang, B. Y. and Adams, N. R.J. Endocrinol., 85: 291-297, 1980; Aldercreutz, H.et al., J. Steroid Biochem. Mol. Biol., 44: 147-153, 1993). 또한 피토에스트로겐은 항산화 작용 및 고지혈증, 동맥경화증 치료 효과가 보고되고 있다(Franke, A. A.et al., J. Agric. Food Chem., 42: 1905-1913, 1994). 현재까지 피토에스트로겐 화합물로 가장 잘 알려진 것이 바로 콩의 이소프라본(isoflavones) 화합물인 제니스테인(genistein), 다이제인(daidzein)과 아마인(flaxseed)의 리그난 화합물인 세코이소라리시레시놀(secoisolariciresinol), 마타이레시놀(matairesinol)이다 (Lundh, T. J.et al., J. Assoc. Off. Anal. Chem., 71: 938-941, 1988; Aldercreutz, H.et al., J. Steroid Biochem. Mol. Biol., 44: 147-153, 1993; Hutchins, A. M.et al., J Am. Diet Assoc., 95: 769-774, 1995; Hutchins, A. M.et al., J. Am. Diet Assoc., 95: 545-551, 1995). 이들 화합물들은 사람의 장내미생물에 의해 포유류 이소플라본(mammalian isoflavones) 및 리그난 성분으로 변형되어 생체의 17β-에스트라디올과 경쟁적으로 에스트로겐 결합자리를 차지함으로서 에스트로겐 및 안티에스트로겐 역할을 수행하는 것으로 알려져 있다(Miksikek, R. J.,J. Steroid Biochem. Mol. Biol., 49: 153-160, 1994). 역학적 조사에 의하면 콩을 많이 섭취하는 동양인들은 서양인들에 비해 에스트로겐 의존성 암의 발병이 낮으며, 아울러 콩을 이용하여 만든 가공식품을 많이 섭취하는 일본인은 다른 선진국에 비해 자궁암 및 유방암의 발병률이 낮다는 사실이 밝혀져 있다(Adlercreutz, H.et al., Lancet,342: 1209-1210, 1993; Kirkman, L. M.et al., Nutr. Cancer24: 1-12, 1995). 그리고 콩의 이소프라본 화합물은 폐경기 이후 에스트로겐의 부족으로 나타나는 골절 및 골다공증을 예방하는 효과가 있다고 한다(Draper, C. R.et al., J. Nutr., 127: 1795-1799, 1997; Anderson, J. J. B. and Garner,S. C. Nutr. Res., 17(10): 1617-1632, 1997).Recent epidemiological reports and clinical studies report that antioxidant phytochemicals contained in various cereals and fruit and vegetables are the next-generation therapies that will surpass vitamins, as well as cancer, as well as cancer (including angina, hypertension, diabetes, and dementia) (Hasler, CM, Food Technology, 52 (11): 63-70, 1998). It has been shown to be effective in preventing and treating degenerative chronic diseases. Among these phytochemicals, in particular, isoflavonoids and lignans are the most recently attracted attention (Adlercreutz H., Bailliers Clin. Endocrinol. Metab. 12 (4): 605-623, 1998). These components are diphenol-based compounds, whose structure and molecular weight are similar to steroid estrogen, so-called phytoestrogen. Phytoestrogens have antiestrogen and estrogenic activity and prevent hormone-dependent breast cancer, prostate cancer and colon cancer as well as preventing heart disease, hypertension and osteoporosis, which are common in postmenopausal women (Dwyer, JT et al., J. Am. Diet Assoc., 94: 739-743, 1994. Tang, BY and Adams, NR J. Endocrinol. , 85: 291-297, 1980; et al., J. Steroid Biochem. Mol. Biol. , 44: 147-153, 1993). In addition, phytoestrogens have been reported to have antioxidant effects, hyperlipemia and atherosclerosis (Franke, AA et al., J. Agric. Food Chem. , 42: 1905-1913, 1994). To date, the most well-known phytoestrogen compounds are the isoflavones compounds genistein, daidzein and flaxseed lignan compounds secoisolariciresinol, Mathai is Lecinol (matairesinol) (Lundh, TJ et al, J. Assoc Off Anal Chem, 71:........ 938-941, 1988; Aldercreutz, H. et al, J. Steroid Biochem Mol Biol ., 44: 147-153, 1993; Hutchins, AM et al, J Am Diet Assoc, 95: 769-774, 1995; Hutchins, AM et al, J. Am Diet Assoc, 95:...... 545 -551, 1995). These compounds are known to play an estrogenic and antiestrogenic role as they are transformed into mammalian isoflavones and lignan components by human intestinal microorganisms and occupy estrogen binding sites competitively with the 17β-estradiol in vivo (Miksikek , RJ, J. Steroid Biochem. Mol. Biol. , 49: 153-160, 1994). According to epidemiological studies, Asians who consume a lot of soybeans are less likely to develop estrogen-dependent cancers than those of Westerners, and the Japanese who consume a lot of processed foods made from soybeans have a lower incidence of uterine cancer and breast cancer than other advanced countries (Adlercreutz, H. et al., Lancet, 342: 1209-1210, 1993; Kirkman, LM et al., Nutr. Cancer 24: 1-12, 1995). And soybean isoflavone compounds have the effect of preventing fractures and osteoporosis caused by a lack of estrogen after menopause (Draper, CR et al., J. Nutr. , 127: 1795-1799, 1997; Anderson, JJB and Garner, SC Nutr Res ., 17 (10): 1617-1632, 1997).
한편, 유량종자 자원으로 중요한 아마인(flaxseed)은 여성호르몬 의존성 암을 예방할 뿐 아니라 여성 호르몬의 대사에 영향을 주어 폐경기를 지연시키는 효과가 있음이 밝혀지고 있다(Orcheson, L.et al., Fed. Am. Soc. Exp. Biol.J., 7: 291-296, 1993; Phipps, W. R.et al., J. Clin. Endocrinol. Metab.,77: 1215-1219, 1993).On the other hand, flaxseed, which is important as a flow seed resource, has been shown to not only prevent female hormone-dependent cancers, but also to affect the metabolism of female hormones to delay postmenopause (Orcheson, L. et al., Fed J. Am. Soc. Exp. Biol., J., 7: 291-296, 1993; Phipps, WR et al., J. Clin. Endocrinol. Metab., 77: 1215-1219, 1993).
이와 같이, 이소플라보노이드 및 리그난과 같은 피토에스트로겐을 함유한 식물들은 유방암, 전립선암, 대장암과 같은 암 뿐만 아니라 골다공증 및 심장순환기질환을 치료할 수 있는 유용생약으로서 크게 각광을 받을 수 있으며, 여러 식물 중 특히 콩 및 아마인과 같이 식물종자에 피토에스트로겐 화합물이 많이 함유되어 있는 것으로 보고되고 있다(Adlercreutz H., Boca Raton, Fla: CRC Press Inc., 137-196, 1991; Thompson, L. U.et al., Nutr. Cancer16: 43-52, 1991).Thus, plants containing phytoestrogen, such as isoflavonoids and lignans, can be greatly appreciated as useful medicines for treating osteoporosis and cardiovascular diseases as well as cancers such as breast cancer, prostate cancer and colon cancer, In particular, it has been reported that phytoestrogen compounds are abundantly contained in plant seeds such as soybean and flax (Adlercreutz H., Boca Raton, Fla: CRC Press Inc., 137-196, 1991; Thompson, LU et al., Nutr Cancer 16: 43-52, 1991).
따라서 민간에서 알려지고 있는 홍화씨의 골다공증 및 골절 치료 효과 및 여성의 월경 기간 연장 효과는 피토에스트로겐 화합물로 기인되었을 가능성이 있었다. 조사한 결과, 놀랍게도 볶은 홍화씨에는 항산화성 피토에스트로겐 화합물로 알려진 리그난 성분인 마타이레시놀(matairesinol)과 그 유사물질인 하이드록시악티게닌(hydroxyarctigenin) 성분, 그리고 콩의 제니스테인(genistein)과 유사한 플라보노이드 성분인 틸리아닌(tilianine)과 아카세틴(acacetin) 성분이 함유되어 있음을 확인할 수 있었다(Choi, S. W.et al., J. Food Sci. and Nutr., 4(4): 25-29, 1999). 또한 홍화씨에 다량으로 존재하는 항산화성 세로토닌 성분이 뼈 형성에 중대한 영향을 미칠 것으로 예상되었다.Therefore, it is possible that the effect of treatment of osteoporosis and fracture of safflower seed, which is known in the private sector, and the lengthening of menstrual period of women are attributable to phytoestrogen compounds. Surprisingly, surprisingly, roasted safflower seeds contain mallowiresin, a lignan ingredient known as an antioxidant phytoestrogen compound, hydroxyarctigenin, a similar ingredient, and tylli, a flavonoid component similar to soybean genistein, Tilianine and acacetin (Choi et al., J. Food Sci. And Nutr. , 4 (4): 25-29, 1999). In addition, antioxidant serotonin, which is abundant in safflower seed, is expected to have a significant impact on bone formation.
홍화씨로부터 세로토닌, 리그난 및 플라보노이드의 분리는 사카무라 사다오(Agric. Biol. Chem., 44(12): 2951-2954, 1980) 등에 의해 보고된 바 있으나 이 방법은 탈지 홍화씨의 메탄올 추출액에 물과 에틸아세테이트를 가하여 얻어진 에틸아세테이트 가용부를 실리카겔 크로마토그래피를 실시하여 위의 3가지 물질을 순차적으로 분리하는 방법으로서 에틸아세테이트에 용해되지 않은 위의 3가지 혼합물은 제외됨으로써 추출효과가 낮고, 또 실리카겔 칼럼크로마토그래피 단독 방법으로는 세로토닌, 리그난 및 플라보노이드 화합물의 각 구성성분을 효과적으로 분리할 수 없기 때문에 실질적으로 이용하기가 어려운 단점이 있다. 또한 각 성분이 골격 형성에 미치는 효과에 대해서는 전혀 알려져 있지 않다.Separation of serotonin, lignans and flavonoids from safflower seeds has been reported by Sakamura Sadao ( Agric. Biol. Chem ., 44 (12): 2951-2954, 1980), but this method uses water and ethyl acetate The ethyl acetate-soluble fraction obtained was subjected to silica gel chromatography to sequentially separate the above three substances. As a result, the above three compounds not dissolved in ethyl acetate were excluded, thereby lowering the extraction effect. Further, the silica gel column chromatography alone There is a disadvantage in that it is difficult to effectively utilize each component of serotonin, lignan and flavonoid compound because it can not be effectively separated. Also, the effect of each component on skeletal formation is not known at all.
따라서 본 발명자들은 볶은 홍화씨로부터 고순도의 세로토닌, 리그난 및 플라보노이드 성분을 분리하였고 세포배양에 의해 정립시켰으며 볶은 홍화씨에 들어있는 6가지 폴리페놀성분 중 리그난 및 세로토닌 성분이 기존의 피토에스트로겐 화합물로 알려진 17베타-에스트라디올 및 제니스테인 성분과 유사하게 뼈 형성을 촉진함을 확인하므로써 본 발명을 완성하였다.Therefore, the present inventors isolated high purity serotonin, lignan and flavonoid components from roasted safflower seeds and cultured them by cell culture. Of the six polyphenols contained in roasted safflower seeds, lignans and serotonin components are known to be 17 beta - promoting bone formation similar to estradiol and genistein components.
따라서 본 발명의 목적은 볶은 홍화씨로부터 뼈 형성을 촉진하여 골절 및 골다공증 치료에 유용한 세로토닌, 리그난 및 플라보노이드 성분의 추출방법을 제공함에 있다.Accordingly, an object of the present invention is to provide a method for extracting serotonin, lignan and flavonoid components, which is useful for treating bone formation from roasted safflower seeds and treating fractures and osteoporosis.
본 발명의 상기 목적은 볶은 홍화씨로부터 60%, 80% 및 100% 수용성 메탄올 용액으로 추출한 후, 상기 60%, 80% 및 100% 메탄올 추출물을 농축한 후 다시 세파덱스 LH-20 칼럼 및 분취-고속액체 크로마토그래피하여 세로토닌, 리그난 및 플라보노이드 성분을 분리하였으며 상기 홍화씨로부터 분리한 성분들의 뼈 형성 촉진작용에 대한 효과를 조사함으로써 달성하였다.The above object of the present invention is achieved by extracting 60%, 80% and 100% water-soluble methanol solution from roasted safflower seeds and then concentrating the 60%, 80% and 100% methanol extracts and further adding them to Sephadex LH-20 column and fraction- The serotonin, lignan and flavonoid components were separated by liquid chromatography, and the effects of the components isolated from the safflower seeds on bone formation promoting action were investigated.
이하 본 발명의 구성 및 작용을 설명한다.The configuration and operation of the present invention will be described below.
도 1은 본 발명 볶은 홍화로부터 분리된 6가지 페놀화합물의 분취-고속액체크로마토그람 결과를 나타낸 그래프이다.1 is a graph showing an aliquot-high-speed liquid chromatogram of six phenolic compounds isolated from roasted safflower of the present invention.
본 발명은 볶은 홍화씨로부터 지방을 제거한 후 열탕추출한 다음 60% 수용성 메탄올을 가하여 가용화하여 다이아이온 HP-20 칼럼에 흡착시킨 후 60%, 80% 및 100% 수용성 메탄올 용액으로 추출하고 상기 추출액을 농축한 후 세파덱스 LH-20 칼럼 크로마토그래피하여 폴리페놀화합물인 세로토닌, 리그난 및 플라보노이드 성분을 분리하는 단계; 상기와 동일한 방법으로 홍화씨로부터 폴리페놀화합물을 추출하되 80% 수용성 메탄올을 가하여 가용화하여 폴리아마이드 C-200 칼럼에 흡착시켜 폴리페놀화합물을 순수 분리하는 단계; 상기와 동일한 방법으로 홍화씨로부터 폴리페놀화합물을 추출하되 80% 수용성 메탄올을 가하여 가용화하여 Sep-Pak C18카트리즈에 통과시킨 후 분취-고속액체크로마토그래피하여 폴리페놀화합물을 순수 분리하는 단계; 상기 순수 분리된 성분의 뼈 형성 촉진작용에 대한 효과를 조사하는 단계로 구성된다.In the present invention, fat is removed from roasted safflower seeds, and then the mixture is extracted with hot water, followed by solubilization with 60% water-soluble methanol, adsorbed on a Diaion HP-20 column, extracted with 60%, 80% and 100% aqueous methanol solutions, Followed by Fusepadex LH-20 column chromatography to isolate the polyphenolic compounds serotonin, lignan and flavonoid components; The polyphenol compound is extracted from safflower seed in the same manner as described above, followed by solubilization by adding 80% water-soluble methanol and adsorbing it on a polyamide C-200 column to purely isolate the polyphenol compound; In the same manner as above, the polyphenol compound was extracted from safflower seed, solubilized by adding 80% water-soluble methanol, passed through a Sep-Pak C 18 column and purified by preparative-high performance liquid chromatography to purely isolate the polyphenol compound. And examining the effect of the purely isolated component on bone formation promoting action.
본 발명에서 사용한 메탄올의 바람직한 농도는 50 내지 120% 수용액이며 가장 바람직하기는 60 내지 100% 수용액이다. 이 때 추출용매를 메탄올 대신 에탄올을 사용할 수 있다.The preferred concentration of methanol used in the present invention is 50-120% aqueous solution, most preferably 60-100% aqueous solution. In this case, ethanol may be used as an extraction solvent instead of methanol.
본 발명에서 열탕추출하는 단계에서 바람직한 온도는 70 내지 90℃이며 가장 바람직하기는 80℃이다.In the present invention, the temperature is preferably 70 to 90 ° C, and most preferably 80 ° C.
이하 본 발명의 구체적인 방법을 실시예를 들어 상세히 설명하고자 하지만 본 발명의 권리범위는 이들 실시예에만 한정되는 것은 아니다.Hereinafter, specific methods of the present invention will be described in detail with reference to Examples, but the scope of the present invention is not limited to these Examples.
실시예 1Example 1
본 실시예에서 건조 홍화씨 100 g을 200-250℃에서 5분간 볶은 후 분쇄한 다음 여기에 100% 노르말 핵산 1 L를 가하여 2시간 열탕에서 추출하여 기름을 제거하였다. 상기 추출조작을 2회 반복 실시하여 지방을 제거하고 남은 잔사에 60% 수용성 메탄올 1 L를 가하여 열탕에서 2시간 추출·여과한다. 상기의 추출조작을 2회 반복 실시하여 얻은 메탄올 추출액을 200 mL까지 감압·농축한 다음 여기에 다시 100% 노르말 핵산 500 mL를 가하여 핵산층으로 떠오르는 기름을 제거하였다. 그 다음 메탄올 추출액에 60% 수용성 메탄올 100 mL을 가하여 혼합한 후 여과하고 그 여액 전량을 다이아이온 HP-20(미츠비씨화학, 일본) 500 g으로 충진시킨 직경 5 cm의 칼럼으로 옮기고 물, 20% 수용성 메탄올, 40% 수용성 메탄올, 60% 수용성 메탄올, 80% 수용성 메탄올 및 100% 메탄올 용액 1 L를 각각 차례로 용출하였다. 여기서 60% 수용성 메탄올 추출액을 감압·농축시켜 얻은 건조물질 0.2 g을 메탄올로 녹인 후 세파덱스 LH-20(파아마시아, 스웨덴) 100 g으로 충진시킨 직경 2 cm의 칼럼으로 옮기고 메탄올 1 L으로 튜브당 5 mL씩 100개 분획으로 나누어 용출하여 N-페루로릴세로토닌(N-feruloylserotonin, 분자량 352, 녹는점 118℃) 86 mg과 N-(파라-쿠마로일)세로토닌(N-(p-coumaroyl)serotonin, 분자량 322, 녹는점 194℃) 73 mg을 각각 얻었다(수율 각각 86 및 73 mg%, 건조 홍화씨 기준). 그 다음, 상기와 같은 방법으로 80% 메탄올 추출물 45 mg을 세파덱스 LH-20 칼럼 크로마토그래피를 실시하여 마타이레시놀(matairesinol, 분자량 358, 녹는점 94℃) 7 mg과 8'-하이드록시악티게닌(8'-hydroxyarctigenin, 분자량 388, 녹는점 168℃) 25 mg을 각각 얻었다(수율 각각 7 및 25 mg%, 건조 홍화씨 기준). 100% 메탄올 추출물 76 mg을 상기와 같은 방법으로 세파덱스 LH-20 칼럼크로마토그래피를 실시하여 틸리아닌 (tilianine, 분자량 446, 녹는점 125℃) 11 mg과 아카세틴(acacetin, 분자량 284, 녹는점 255℃) 52 mg을 각각 얻었다(수율 각각 11 및 52 mg%, 건조 홍화씨 기준).In this Example, 100 g of dried safflower seed was roasted at 200-250 ° C for 5 minutes and then pulverized. Then, 1 L of 100% normal nucleic acid was added thereto, and the oil was removed by extraction in hot water for 2 hours. The extraction operation is repeated twice to remove the fat, and 1 L of 60% water-soluble methanol is added to the remaining residue, followed by extraction and filtration for 2 hours in a hot water bath. The above extraction operation was repeated twice. The methanol extract was concentrated to 200 mL, and then 500 mL of 100% normal nucleic acid was added thereto to remove oil floating in the nucleic acid layer. Then, 100 mL of 60% water-soluble methanol was added to the methanol extract, followed by filtration. The filtrate was transferred to a 5 cm diameter column packed with 500 g of Diaion HP-20 (Mitsubishi Chemical, Japan) Water-soluble methanol, 40% water-soluble methanol, 60% water-soluble methanol, 80% water-soluble methanol and 1 L of a 100% methanol solution were respectively eluted. Here, 0.2 g of a dry substance obtained by reducing and concentrating the 60% water-soluble methanol extract was dissolved in methanol, transferred to a column having a diameter of 2 cm filled with 100 g of Sephadex LH-20 (Parmasia, Sweden) the eluted sugar divided into 100 fractions by 5 mL serotonin reel in Peru N- (N-feruloylserotonin, molecular weight 352, melting point 118 ℃) and 86 mg N- (para-one as circles) serotonin (N- (p -coumaroyl ) serotonin, molecular weight 322, melting point 194 ° C), respectively (yield: 86 and 73 mg%, respectively). Then, 45 mg of 80% methanol extract was subjected to Sephadex LH-20 column chromatography to obtain 7 mg of matairesinol (molecular weight 358, melting point 94 ° C) and 8 mg of 8'-hydroxyactyzine (8'-hydroxyarctigenin, molecular weight 388, melting point 168 ° C) (yield: 7 and 25 mg%, respectively). 76 mg of 100% methanol extract was subjected to Sephadex LH-20 column chromatography in the same manner as described above to give 11 mg of tilianine (molecular weight 446, melting point 125 ° C) and acacetin (molecular weight 284, melting point 255 ℃) (yield: 11 and 52 mg%, respectively, based on dried safflower seed).
실시예 2Example 2
볶은 홍화씨 100 g을 분쇄한 후 여기에 80% 수용성 메탄올 1 L를 가하여 열탕에서 2시간 추출·여과하였다. 상기 추출조작을 3회 반복 실시하여 얻은 메탄올 추출액을 200 mL까지 감압·농축한 후 100% 노르말 핵산 500 mL를 가하여 핵산층과 메탄올층으로 분획하여 핵산에 추출되는 기름을 제거하였다. 그 다음, 메탄올 추출물을 100 mL까지 감압·농축한 후 여과하고 그 여액 전량을 폴리아마이드 C-200(화광순약공업(주), 일본) 100 g으로 충진시킨 직경 5 cm의 칼럼으로 옮기고 20% 수용성 메탄올, 60% 수용성 메탄올 및 100% 메탄올 용액 1 L를 각각 차례로 용출하였다. 그 중 20% 메탄올 분획에서 플라보노이드 혼합물 54 mg, 60% 메탄올 분획에서 리그난 혼합물 38 mg, 그리고 100% 메탄올 분획에서 세로토닌 혼합물 0.15 g을 각각 얻었다. 그 다음 플라보노이드 분획 54 mg을 메탄올로 녹인 후 세파덱스 LH-20(파아마시아, 스웨덴) 50 g으로 충진시킨 직경 2 cm의 칼럼으로 옮기고 메탄올 1 L로 튜브당 2 mL씩 100개 분획으로 나누어 용출하여 틸리아닌(tilianine, 분자량 446, 녹는점 125℃) 7 mg과 아카세틴(acacetin, 분자량 284, 녹는점 255℃) 37 mg을 각각 얻었다(수율 각각 7 및 37 mg%, 건조 홍화씨 기준). 상기와 같은 방법으로 리그난 혼합물 38 mg을 세파덱스 LH-20 칼럼 크로마토그래피를 실시하여 마타이레시놀(matairesinol, 분자량 358, 녹는점 94℃) 5 mg과 8'-하이드록시악티게닌(8'-hydroxyarctigenin, 분자량 388, 녹는점 168℃) 20 mg을 각각 얻었다(수율 각각 5 및 20 mg%, 건조 홍화씨 기준). 마지막으로 세로토닌 혼합물 0.15 g을 상기와 같은 방법으로 세파덱스 LH-20 칼럼 크로마토그래피를 실시하여 N-페루로릴세로토닌(N-feruloylserotonin, 분자량 352, 녹는점 118℃) 76 mg과 N-(파라-쿠마로일)세로토닌(N-(p-coumaroyl)serotonin, 분자량 322, 녹는점 194℃) 59 mg을 각각 얻었다(수율 각각 76 및 59 mg%, 건조 홍화씨 기준).100 g of roasted safflower seed was pulverized, and 1 L of 80% water-soluble methanol was added thereto, followed by extraction and filtration for 2 hours in a hot water bath. The extraction procedure was repeated three times. The methanol extract was concentrated to 200 mL, and then 500 mL of 100% normal nucleic acid was added to separate the nucleic acid layer and the methanol layer to remove the oil extracted in the nucleic acid. Then, the methanol extract was reduced to 100 mL, concentrated, filtered, and transferred to a column having a diameter of 5 cm filled with 100 g of Polyamide C-200 (Hikyu Pure Chemical Industries, Japan) Methanol, 1% aqueous solution of 60% water-soluble methanol and 100% methanol, respectively. In the 20% methanol fraction, 54 mg of the flavonoid mixture, 38 mg of the lignan mixture in the 60% methanol fraction and 0.15 g of the serotonin mixture in the 100% methanol fraction were obtained, respectively. Then 54 mg of the flavonoid fraction was dissolved in methanol and transferred to a column of 2 cm in diameter packed with 50 g of Sephadex LH-20 (Parmasia, Sweden). Each fraction was divided into 100 fractions , 7 mg of tilianine (molecular weight 446, melting point 125 ° C) and 37 mg of acacetin (acacetin, molecular weight 284, melting point 255 ° C) were obtained, respectively. 38 mg of the lignan mixture was subjected to Sephadex LH-20 column chromatography to obtain 5 mg of matairesinol (molecular weight 358, melting point 94 ° C) and 8'-hydroxyarctigenin , Molecular weight: 388, melting point: 168 캜) (yield: 5 and 20 mg%, respectively). Finally, 0.15 g of the serotonin mixture was subjected to Sephadex LH-20 column chromatography in the same manner as described above to obtain 76 mg of N-feruloylserotonin (molecular weight 352, melting point 118 캜) one to Kumar) serotonin (N- (p -coumaroyl) serotonin, molecular weight 322, respectively, to give the 59 mg melting point 194 ℃) (yield based on each of 76 and 59 mg%, dry safflower).
실시예 3Example 3
볶은 홍화씨 100 g을 분쇄한 후 여기에 100% 노르말 핵산 1 L를 가하여 3시간 열탕에서 추출하여 기름을 제거하였다. 상기의 추출조작을 2회 반복 실시하여 얻은 잔사에 80% 수용성 메탄올을 가하여 열탕에서 2시간 추출·여과하였다. 상기의 추출조작을 3회 반복 실시하여 얻은 메탄올 추출액을 100 mL까지 감압·농축하였다. 여기에 에틸아세테이트 500 mL를 넣고 에틸아세테이트층과 수층으로 분획한후 에틸아세테이트추출물을 1.7 g을 얻었다. 이것을 10 mL 80% 수용성 메탄올로 용해한 후 Sep-Pak C18카트리즈(워터스, 미국)에 통과시켜 얻은 추출액을 메탄올로 적당히 희석한 후 분취-고속액체크로마토그래피에서 반복하여 분리 및 정제하여 N-페루로릴세로토닌(N-feruloylserotonin, 분자량 352, 녹는점 118℃) 78 mg, N-(파라-쿠마로일)세로토닌(N-p-coumaroylserotonin, 분자량 322, 녹는점 194℃) 67 mg(수율 각각 78 및 67 mg%, 건조 홍화씨 기준), 마타이레시놀(분자량 358, 녹는점 94℃) 5 mg과 8'-하이드록시악티게닌(8'-hydroxyarctigenin, 분자량 388, 녹는점 168℃) 24 mg(수율 각각 5 및 24 mg%, 건조 홍화씨 기준), 그리고 틸리아닌(tilianine , 분자량 446, 녹는점 125℃) 10 mg과 아카세틴(acacetin, 분자량 284, 녹는점 255℃) 47 mg을 각각 얻었다(수율 각각 10 및 47 mg%, 건조 홍화씨 기준).After roasting 100 g of roasted safflower seeds, 1 L of 100% normal nucleic acid was added thereto, and the oil was extracted by extraction from hot water for 3 hours. The above extraction operation was repeated twice, and 80% water-soluble methanol was added to the residue, followed by extraction and filtration for 2 hours in a hot water bath. The above extraction procedure was repeated three times and the methanol extract solution was reduced to 100 mL and concentrated. 500 mL of ethyl acetate was added thereto, and the mixture was divided into an ethyl acetate layer and an aqueous layer, and 1.7 g of an ethyl acetate extract was obtained. This was dissolved in 10 mL of 80% water-soluble methanol, passed through Sep-Pak C 18 cartridges (Waters, USA), and the resulting extract was diluted with methanol and then separated and purified by preparative high performance liquid chromatography. 78 mg of N-feruloylserotonin (molecular weight 352, melting point 118 캜), 67 mg of N- (para-coumaroyl) serotonin (N- p -coumaroylserotonin, molecular weight 322, melting point 194 캜) 5 mg of matairecinol (molecular weight 358, melting point 94 ° C) and 24 mg of 8'-hydroxyarctigenin (molecular weight 388, melting point 168 ° C) (yield: 67 mg, based on dried safflower seed) 10 mg of tilianine (molecular weight 446, melting point 125 ° C) and 47 mg of acacetin (molecular weight 284, melting point 255 ° C) were obtained respectively (yield: 5 and 24 mg%, based on dried safflower seed) 10 and 47 mg%, based on dried safflower seed).
이 때 분취-고속액체크로마토그래피의 조건은 다음과 같았다. 워터스 델타 프렙 4000 고속액체크로마토그래피; 칼럼, RCM Novapak C18(25mm × 100mm × 2 cartridge); 자외선 검출기(UV300용매 B로 60분간 농도구배용출). 그리고 이 때 분리된 6가지 화합물의 분취-고속액체크로마토그램은 도 1에 나타낸 바와 같았으며, 이들의 상세한 자외선, 적외선 및 질량분석 데이터는 표 1에 나타낸 바와 같았다. 수소-핵자기공명 데이터와 탄소-핵자기공명 데이터는 각각 표 2a, 2b와 표 3a, 3b에 나타낸 바와 같았다.The conditions for preparative-high performance liquid chromatography were as follows. Waters Delta prep 4000 high performance liquid chromatography; Column, RCM Novapak C 18 (25 mm x 100 mm x 2 cartridges); Ultraviolet detector (concentration gradient elution for 60 min with UV 300 solvent B). The preparative-high-speed liquid chromatograms of the six compounds thus separated were as shown in Fig. 1, and their detailed ultraviolet, infrared and mass spectral data were as shown in Table 1. Hydrogen-nuclear magnetic resonance data and carbon-nuclear magnetic resonance data were as shown in Tables 2a and 2b and Tables 3a and 3b, respectively.
세로토닌은 치환기에 따라 (a)N-페루로일세로토닌 또는 (b)N-(파라-쿠마로일)세로토닌이며, 일반식은 하기 일반식 (I)과 같았다;Serotonin is (a) N-perroyl serotonin or (b) N- (para-coumaroyl) serotonin depending on the substituent, and the general formula is the same as the following general formula (I);
(a) N-페루로일세로토닌(S1) : 여기서 R1=H, R2=OCH3, R3=H 이다.(a) N-perroyl serotonin (S1): wherein R 1 = H, R 2 = OCH 3 , R 3 = H.
(b) N-(파라-쿠마로일)세로토닌(S2) : 여기서 R1=H, R2=H, R3=H 이다.(b) N- (para-coumaroyl) serotonin (S2): wherein R 1 = H, R 2 = H, R 3 = H.
리그난은 치환기에 따라 (a)마타이레시놀 또는 (b)8'-하이드록시악티게닌이며 일반식은 하기 일반식 (II)와 같았다;The lignan is (a) matairecinol or (b) 8'-hydroxyactigene according to the substituent, and the general formula is as shown in the following general formula (II);
(a) 마타이레시놀(L1) : 여기서 R1=H, R2=H, R3=H 이다.(a) mathiasecinol (L1): wherein R 1 = H, R 2 = H, and R 3 = H.
(b) 8'-하이드록시악티게닌(L2) : 여기서 R1=CH3, R2=H, R3=OH 이다.(b) 8'-hydroxyactigene (L2): wherein R 1 = CH 3 , R 2 = H, R 3 = OH.
플라보노이드는 치환기에 따라 (a)틸리아닌 또는 (b)아카세틴이며 일반식은하기 일반식 (III)과 같았다;Depending on the substituent, the flavonoid is either (a) tilylene or (b) acacetin and the general formula is as in formula (III) below;
(a) 틸리아닌(F1) : 여기서 R1=글루코스, R2=CH3이다.(a) Tilylene (F1): wherein R 1 = glucose and R 2 = CH 3 .
(b) 아카세틴(F2) : 여기서 R1=H, R2=CH3이다.(b) Acacetin (F2): wherein R 1 = H and R 2 = CH 3 .
실험예 1: 분리된 폴리페놀화합물의 뼈 형성 촉진작용에 대한 효과Experimental Example 1: Effect of the isolated polyphenol compound on bone formation promoting action
본 실험예에서 상기 실시예 1, 2, 3에서 얻은 폴리페놀화합물 즉, 세로토닌 성분인 페루로릴세로토닌 및 쿠마릴세로토닌, 리그난 성분인 마타이레시놀 및 하이드록시악티게닌, 플라보노이드 성분인 틸리아닌 및 아카세틴의 뼈 형성 촉진작용에 대한 효과를 조사하기 위하여 뼈를 형성하는 골세포인 뼈모세포(osteoblast) 세포주(cell line)인 ROS 17/2.8를 사용하여 측정하였다. 즉 ROS 17/2.8 세포를 페놀레드가 첨가되지 않은 10% 소태아혈청(fetal bovine serum)과 1% 항생제-항균제 혼합물(100 IU 페니실린, 100 mg 스트렙토마이신, 250 ng 암포테리신, Gibco BRL)을 첨가한 덜베코 변형 이글배지(Dulbecco's Modified Eagle medium)에 접종하여 37℃로 유지된 5% CO2배양기에서 배양하면서 세포증식(cell proliferation)을 엠티티(MTT, 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyltetrazolin bromide)의 대사환원에 근거한 MTT 검정 방법으로 측정하였다. 이 때 홍화씨의 성분이 뼈 형성을 촉진하는지 판단하기 위하여, 골세포 증식을 촉진한다고 이미 알려진 17β-에스트라디올(17β-estradiol)과 콩에서 분리한 제니스테인(genistein)을 비교구(positive reference)로 설정하고 시료 무첨가구를 대조구(control)로 설정하여 비교하였다. MTT 검정 방법은 다음과 같았다. ROS 세포를 96 웰(well)에 세포수가 5 × 103이 되도록 심고난 후 소태아혈청의 효과를 배제하기 위하여 24시간동안 0.5% 에스트로겐 결핍-소태아혈청으로 배지조성을 바꾸어 주었으며, 2.5% 에스트로겐 결핍-소태아혈청 조건하에서 에스트로겐, 제니스테인 외에도 볶은 홍화씨으로부터 분리된 6가지 페놀화합물을 10-6∼10-15몰농도로 48시간 동안 자극하였다. 각 웰(well)에 엠티티(1.1 mg/mL) 용액 50 ㎕를 첨가하여 37℃에서 4시간 동안 배양하였다. 엠티티에 의해 형성된 보랏빛의 침전물인 포르마잔 결정체(formazan crystal)를 녹이기 위하여 디메틸설폭사이드(dimethylsulfoxide) 150 ㎕를 첨가하여 녹인 다음 각 웰(well)의 흡광도를 마이크로플레이트 리더(microplate reader)를 사용하여 540 nm에서 측정하였다. 이 때 각 성분의 뼈 형성 촉진작용은 대조구(control)에 대한 상대치로 나타내었다. 그 결과는 하기 표 4와 같았다.In the present experimental example, the polyphenol compounds obtained in Examples 1, 2 and 3, namely, perrolyl serotonin and coumaryl serotonin, which are serotonin components, matairecinol and hydroxyactigenein, lignan components, tyllian, In order to investigate the effect of cetin on the bone formation promoting action, the osteoblast cell line, bone cell forming bone, was measured using ROS 17 / 2.8. (100 IU penicillin, 100 mg streptomycin, 250 ng amphotericin, Gibco BRL) supplemented with 10% fetal bovine serum and 1% antibiotic-antimicrobial agent without phenol red (MTT, 3- (4,5-dimethyl-l, 3-dihydro-lH-pyrazol-3-yl) -ethanone was prepared by incubating in Dulbecco's Modified Eagle medium and incubating in a 5% CO 2 incubator maintained at 37 & thiazol-2-yl) -2,5-diphenyltetrazolin bromide) by the MTT assay method based on the metabolic reduction. At this time, 17β-estradiol (17β-estradiol), which is known to promote osteocyte proliferation, and genistein isolated from soybean were set as a positive reference in order to determine whether the ingredient of safflower seed promotes bone formation. And control without addition of sample. The MTT assay method was as follows. ROS cells were seeded in 96 wells at a density of 5 × 10 3 cells. To eliminate the effect of fetal bovine serum, the culture medium was changed with 0.5% estrogen deficiency-fetal bovine serum for 24 hours. 2.5% estrogen deficiency - Six phenolic compounds isolated from roasted safflower seeds in addition to estrogen and genistein under fetal serum conditions were stimulated for 48 hours at 10 -6 to 10 -15 molar concentrations. To each well, 50 μl of a solution of Melti (1.1 mg / ml) was added and cultured at 37 ° C for 4 hours. 150 μl of dimethylsulfoxide was added to dissolve the formazan crystal, which was a violet precipitate formed by the emittie, and the absorbance of each well was measured using a microplate reader to determine the absorbance of 540 nm. At this time, the bone formation promoting action of each component was expressed as a relative value to the control (control). The results are shown in Table 4 below.
상기 표 4에서 보에 나타낸 바와 같이, 17베타-에스트라디올(E2)은 낮은 농도인 10-15M에서 이미 130% 정도의 세포증식 효과를 나타내었으며, 생리적 농도인 10-9M에서 약 140%까지 증가하여 용량의존적으로 골세포의 증식을 촉진하였다. 콩의 제니스테인도 용량 의존적으로 ROS 골세포 증식을 최고 115% 정도 증가시켰지만, 에스트라디올(E2)보다 낮은 효과를 나타내었다. 볶은 홍화씨로부터 분리된 6가지 폴리페놀화합물도 모두 용량의존적으로 ROS 골세포의 증식을 촉진하는 경향이었으며, 특히 마타이레시놀과 아카세틴 화합물은 각각 에스트라디올(E2)과 제니스테인 만큼의 높은 세포증식률을 나타내었다.As shown in the above Table 4, 17 beta-estradiol (E 2 ) already exhibited a cell proliferation effect of about 130% at a low concentration of 10 -15 M, and a physiological concentration of about 10 -9 M to about 140 %, Which promoted proliferation of bone cells in a dose dependent manner. Soybean genistein also increased ROS osteoprotein proliferation by up to 115% in a dose-dependent manner, but showed lower efficacy than estradiol (E 2 ). All six polyphenols isolated from roasted safflower seeds showed a dose - dependent tendency to promote the proliferation of ROS bone cells. In particular, matairecinol and acacetin compounds showed cell proliferation rates as high as those of estradiol (E 2 ) and genistein Respectively.
상기 표 4의 결과로부터 볶은 홍화씨로부터 분리된 6가지 폴리페놀성분 중 마타이레시놀과 아카세틴 성분은 뼈 형성을 촉진하는 에스트로겐 화합물인 17β-에스트라디올, 제니스테인의 대체제로써 작용할 수 있음이 밝혀졌다.From the results shown in Table 4, it was found that among the six polyphenols isolated from roasted safflower seeds, matairecinol and acacetin can act as substitutes for 17β-estradiol and genistein, which are estrogen compounds promoting bone formation.
이상 실시예와 실험예를 통하여 설명한 바와 같이, 볶은 홍화씨를 핵산으로 탈지하여 얻은 잔사를 메탄올로 열탕 추출하고 여과·농축한 후 다이아이온 HP-20 및 폴리아마이드 C-200으로 칼럼크로마토그래피를 실시하여 얻어진 60%, 80% 및 100% 메탄올 추출물을 세파덱스 LH-20으로 칼럼크로마토그래피 및 분취-고속액체크로마토그래피를 실시하여 순수 분리한 세로토닌, 리그난 및 플라보노이드 성분은 골다공증 및 골절 치료에 뛰어난 효과가 있으므로 골다공증 및 골절 치료용 기능성 식품 및 의약품의 원료 산업상 매우 유용한 발명인 것이다.The roasted safflower seeds obtained by defatting roasted safflower seeds with a nucleic acid were extracted with hot water with methanol, filtered and concentrated, and subjected to column chromatography using Diaion HP-20 and polyamide C-200 The serotonin, lignan and flavonoid components purified by column chromatography and fractionation-high performance liquid chromatography on the obtained 60%, 80% and 100% methanol extracts with Sephadex LH-20 were excellent in the treatment of osteoporosis and fracture It is a very useful invention in the raw material industry of functional foods and medicines for the treatment of osteoporosis and fracture.
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020000003048A KR100345825B1 (en) | 2000-01-22 | 2000-01-22 | Method for Extraction, Isolation and Identification of Serotonins, Lignans and Flavonoids Improved Bone Formation from Safflower(Carthamus tinctorious L.) Seeds |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020000003048A KR100345825B1 (en) | 2000-01-22 | 2000-01-22 | Method for Extraction, Isolation and Identification of Serotonins, Lignans and Flavonoids Improved Bone Formation from Safflower(Carthamus tinctorious L.) Seeds |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20010034952A KR20010034952A (en) | 2001-05-07 |
KR100345825B1 true KR100345825B1 (en) | 2002-07-24 |
Family
ID=19640637
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020000003048A Expired - Fee Related KR100345825B1 (en) | 2000-01-22 | 2000-01-22 | Method for Extraction, Isolation and Identification of Serotonins, Lignans and Flavonoids Improved Bone Formation from Safflower(Carthamus tinctorious L.) Seeds |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100345825B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102236423B1 (en) | 2020-06-03 | 2021-04-05 | 최홍식 | Nutritious glutinous rice using boiled water from safflower seeds and the process of manufacture thereof |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100408231B1 (en) * | 2000-08-14 | 2003-12-01 | 한국 한의학 연구원 | Flavonoid derivateives for prevention and treatment of osteoporosis |
US7357951B2 (en) * | 2002-04-12 | 2008-04-15 | Ajinomoto Co., Inc. | Composition for preventing atherosclerosis |
KR20060120096A (en) * | 2003-10-10 | 2006-11-24 | 아지노모토 가부시키가이샤 | Plant seed extract composition and preparation method thereof |
KR100911672B1 (en) * | 2008-11-03 | 2009-08-10 | 한국식품연구원 | Health food composition for strengthening bone matrix and separation method of ingredients for strengthening bone matrix |
KR101340081B1 (en) * | 2012-02-14 | 2013-12-11 | 최상원 | Novel preparation method of Mulberry leaf extract for anti-hypertensive, anti-diabetic, and anti-aging and the product of the same |
CN103588696B (en) * | 2013-09-06 | 2016-03-30 | 中国科学院西北高原生物研究所 | High speed adverse current chromatogram prepares serotonin derivative method from safflower seed meal |
KR101628935B1 (en) * | 2014-04-23 | 2016-06-10 | 재단법인 전남생물산업진흥원 | A preparation method of an extract containing polyphenol compounds from safflower seeds using supercritical fluid extraction |
CN104906380A (en) * | 2015-07-02 | 2015-09-16 | 邹吉锋 | External Chinese medicinal preparation for treating bone fracture |
-
2000
- 2000-01-22 KR KR1020000003048A patent/KR100345825B1/en not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102236423B1 (en) | 2020-06-03 | 2021-04-05 | 최홍식 | Nutritious glutinous rice using boiled water from safflower seeds and the process of manufacture thereof |
Also Published As
Publication number | Publication date |
---|---|
KR20010034952A (en) | 2001-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6900240B2 (en) | Method of preparing and using compositions extracted from vegetable matter for the treatment of cancer | |
WO2012055010A1 (en) | Maple tree-derived products and uses thereof | |
KR20090084439A (en) | A composition for the prevention or treatment of diabetic complications containing the extract of Ginseng or a prenylated flavonoid compound isolated therefrom | |
KR100345825B1 (en) | Method for Extraction, Isolation and Identification of Serotonins, Lignans and Flavonoids Improved Bone Formation from Safflower(Carthamus tinctorious L.) Seeds | |
KR20040107713A (en) | Pharmaceutical composition comprising the extract of Scutellaria baicalensis or Baicalin, Baicalein, Wogonin or 5,7,2,5-tetrahydroxy-8,6-dimethoxyflavone isolated therefrom for prevention and inhibition of aging | |
EP2052732A1 (en) | Antioxidant composition containing component originating in the bark of tree belonging to the genus acacia | |
KR100934022B1 (en) | Composition comprising an active ingredient isolated from Bogolgol extract or Bogolgol extract excellent in estrogen activity | |
JP2001064172A (en) | Agent for preventing and treating disease caused by mutation of apc gene | |
JP2003252784A (en) | alpha-GLUCOSIDASE INHIBITOR | |
JP3009599B2 (en) | Treatment agent for osteoporosis containing flavonoid glycoside and edible composition for treatment of osteoporosis | |
KR101153870B1 (en) | Effective Perilla extract for inhibiting neuraminidase | |
KR101834764B1 (en) | Soybean extract with excellent content of the bioactive ingredients | |
JP2004242663A (en) | Diet food | |
KR100354791B1 (en) | Novel Use of Polyphenol Compounds isolated from Safflower(Carthamus tinctorius L.) Seed | |
JP2004210675A (en) | Bone quantity amelioration composition | |
KR20010070841A (en) | Method for Extraction, Isolation and Identification of trans-Resveratrol and Its Derivatives with Anticarcinogenic and Antimutagenic Activity from Paeonia lactiflora Seeds | |
JPH11246426A (en) | Hyperlipemia medicine and food composition containing the same | |
KR101293835B1 (en) | Composition comprising the combined extract of Astragalus membranaceus Bunge and Plantago asiatica for preventing and treating obesity | |
KR20120044450A (en) | Composition for prevention or treatment of osteoporosis comprising extract of cirsii herba | |
KR100640094B1 (en) | A composition comprising green tea seed oil having cholesterol lowering or antioxidant activity | |
KR20180088606A (en) | Ethyl acetate Fraction of Salicornia SPP. Water Extracts Containing Isorhamnetin Having Effect for Prevention or Treatment of Non-alcoholic Fatty Liver Disease | |
KR101472224B1 (en) | Composition for preventing and treating of osteoporosis comprising root extract of Rumex Crispus L. | |
JP5539665B2 (en) | Anti-diabetic agents and their use | |
KR100413964B1 (en) | Composition for preventing and treating cancer comprising isolated compounds and extracts from angelica koreana max and isolating methods thereof | |
TWI260205B (en) | A composition including isoflavones refined from plant |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20000122 |
|
A201 | Request for examination | ||
PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20000211 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 20000122 Comment text: Patent Application |
|
G15R | Request for early publication | ||
PG1501 | Laying open of application |
Comment text: Request for Early Opening Patent event code: PG15011R01I Patent event date: 20010228 |
|
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20011201 Patent event code: PE09021S01D |
|
N231 | Notification of change of applicant | ||
PN2301 | Change of applicant |
Patent event date: 20020207 Comment text: Notification of Change of Applicant Patent event code: PN23011R01D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20020624 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20020711 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20020712 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
PR1001 | Payment of annual fee |
Payment date: 20050630 Start annual number: 4 End annual number: 4 |
|
PR1001 | Payment of annual fee |
Payment date: 20060705 Start annual number: 5 End annual number: 5 |
|
PR1001 | Payment of annual fee |
Payment date: 20070710 Start annual number: 6 End annual number: 6 |
|
PR1001 | Payment of annual fee |
Payment date: 20080710 Start annual number: 7 End annual number: 7 |
|
FPAY | Annual fee payment |
Payment date: 20090710 Year of fee payment: 8 |
|
PR1001 | Payment of annual fee |
Payment date: 20090710 Start annual number: 8 End annual number: 8 |
|
LAPS | Lapse due to unpaid annual fee | ||
PC1903 | Unpaid annual fee |
Termination category: Default of registration fee Termination date: 20110610 |